CRDF - List Of Concerns About Cardiff Oncology's Plk1 Inhibitor

• The market got excited over the efficacy data of onvansertib, Cardiff’s Plk1 inhibitor in mCRC recently.
• We need to keep in mind that mltiple Plk1 inhibitors have failed multiple cancer indications in the past decade.
• Onvansertib’s Phase Ib/II efficacy data in mCRC may not persist in later clinical stages.
• mCRC with KRAS mutation will face more competitions from KRAS mutation-specific inhibitors.

For further details see: